International Stem Cell Corporation

Equities

ISCO

US4603782016

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 18:40:10 15/05/2024 BST			5-day change	1st Jan Change
0.09 ^USD	0.00%		-7.22%	+45.16%

03-28	International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2022

March 30, 2023 at 09:32 pm

International Stem Cell Corporation reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was USD 0.331 million compared to USD 0.899 million a year ago. Basic loss per share from continuing operations was USD 0.04 compared to USD 0.11 a year ago.

Latest news about International Stem Cell Corporation

International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
International Stem Cell Corporation and Dr. Andrey Semechkin Agrees to Extend (Until September 15, 2024) the Maturity Date of the Loan	18/09/23	CI
Bayer says Parkinson's stem cell therapy improves symptoms in initial trial	28/08/23	RE
International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
Bayer claims early lead in Parkinson's stem cell therapy	28/06/23	RE
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	12/05/23	CI
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	30/03/23	CI
International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt	29/03/23	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI
International Stem Cell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/08/22	CI
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	13/05/22	CI
Earnings Flash (ISCO) INTERNATIONAL STEM CELL CORPORATION Reports Q4 Loss $-0.11	30/03/22	MT
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	29/03/22	CI
International Stem Cell Corporation Auditor Raises 'Going Concern' Doubt	28/03/22	CI
International Stem Cell Corporation Announces Resignation of Sophia Garnette as Principal Financial Officer and VP of Legal Affairs and Operations, Effective April 1, 2022	02/02/22	CI
International Stem Cell Corporation announced that it has received $0.25 million in funding	12/01/22	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
International Stem Cell Corporation and S Real Estate Holdings, Llc Enters into Lease Agreement with Rehco Holdings	01/11/21	CI
International Stem Cell Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/08/21	CI
International Stem Cell Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021	14/05/21	CI
International Stem Cell Corporation Reports Earnings Results for the Full Year Ended December 31, 2020	30/03/21	CI
International Stem Cell Corporation announced that it has received $0.35 million in funding	04/03/21	CI
International Stem Cell Corporation and Dr. Andrey Semechkin Agreed to Extend Maturity Date of the Loan Until January 15, 2022	19/01/21	CI
International Stem Cell Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020	12/11/20	CI

Chart International Stem Cell Corporation

Duration

Period

Chart International Stem Cell Corporation

More charts

Company Profile

International Stem Cell Corporation is a clinical-stage biotechnology company that is focused on therapeutic and biomedical product development. The Company is primarily a research and development company, for the therapeutic market, which has focused on advancing potential clinical applications of human parthenogenetic stem cells (hpSCs) for the treatment of various diseases of the central nervous system and liver diseases. The Company's products are based on human cell culture and a type of pluripotent stem cells and hpSCs. The Company's subsidiaries include Lifeline Cell Technology, LLC (LCT), which develops, manufactures and commercializes primary human cell research products for the biomedical market; Lifeline Skin Care, Inc. (LSC), which develops, manufactures and markets a category of anti-aging skin care products for anti-aging market, and Cyto Therapeutics Pty. Ltd. (Cyto Therapeutics) performs research and development (R&D) for the therapeutic market.

Sector

Biotechnology & Medical Research

Calendar

10/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INTERNATIONAL STEM CELL CORPORATION	+45.16%	720K
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B

Other Biotechnology & Medical Research